Pharma: Clinic Roundup
Wednesday, August 14, 2013
Upsher-Smith Laboratories Inc., of Maple Grove, Minn., reported that USL255 (extended-release topiramate), an investigational once-daily formulation for the management of epilepsy, demonstrated equivalent systemic exposure with an improved topiramate's pharmacokinetic profile at steady-state, as measured by a significantly lower Cmax (p =/< 0.001) and higher Cmin (p =/< 0.001), when compared to immediate-release topiramate (TPM-IR) administered twice daily in healthy volunteers.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.